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ABSTRACT 
Scratching behavior observed after epicutaneous 
challenge with the antigen 2,4-dinitrofluorobenzene 
(DNFB) in the ear of BALB/c mice passively sensitized 
with anti-dinitrophenol (DNP). Immunoglobulin (Ig) E 
was characterized pharmacologically and compared 
with that caused by compound 48/80. Although DNFB 
application itself caused scratching behavior in non-
sensitized mice, the number of scratchings apparently 
increased in sensitized mice from 60min after antigen 
application in comparison with non-sensitized control 
mice. Prednisolone, cyproheptadine, dibucaine and 
naloxone significantly inhibited the DNFB-induced
scratching behavior, whereas the histamine H1-
receptor antagonists HSR-609, cetirizine and 
terfenadine only showed a tendency to inhibit 
scratching. Injection of 48/80 into the rostral part of 
the back also caused scratching. The first scratching 
was observed within 10min after injection and lasted 
intermittently for 30min. The 48/80-induced 
scratching was markedly inhibited by cyproheptadine, 
dibucaine and naloxone, but not by prednisolone and 
the histamine H1-receptor antagonists. Ear edema 
caused by DNFB application in sensitized mice was 
markedly inhibited by prednisolone, HSR-609, 
cetirizine, terfenadine and cyproheptadine, whereas 
dibucaine and naloxone failed to affect ear edema. 
These results indicate that scratching behavior could 
be induced in mice in association with an IgE-
mediated allergic cutaneous reaction and that the 
reaction is pharmacologically similar, but not identical, 
to that caused by 48/80. Although histamine is 
considered to participate in the formation of ear 
edema, it may not play an important role in the 
generation of scratching. 
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INTRODUCTION 
The itch is a sensation associated with a strong desire to 
scratch. In many diseases, such as allergic dermatitis, 
chronic renal failure, hepatic cholestasis and diabetes 
mellitus, pruritus is one of the most important 
symptoms.1-4 Particularly in skin diseases, pruritus with an 
extr mely unpleasant sensation is the most significant 
problem, but the mechanisms causing itching remain to 
be elucidated. It is necessary, therefore, to clarify the 
physiological and pathological mechanisms of pruritus. 
At present, however, no established animal model is 
available, because of the difficulties in behavioral animal 
experiments, to investigate pruritus. Clinically, scratch is 
used as an objective measure of itch. In 1995, Kuraishi et
al.5 reported that scratching in mice caused rostral back 
injection of the pruritogenic agents compound 48/80 
(48/80) and substance P may be due to itch, but not 
pain. They also indicated that histamine and algesiogenic 
agents, capsaicin and formalin, were without significant 
effects. 
  In contrast, application of 2,4-dinitrofluorobenzene 
(DNFB), a typical contact sensitizer, on the ear of mice 
sensitized with anti-dinitrophenol (DNP) IgE causes
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biphasic ear edema.6-9 The immediate phase edema 
peaked 1h after DNFB application, is transient and is 
considered to be generated by mast cell mediators, such 
as histamine and serotonin.9 The late phase edema is 
long-lasting and shows a peak 24h after antigen 
application. Pro-inflammatory cytokines, such as tumor
necrosis factor-α and interleukin-1β, are suggested to be
involved in the late-phase edema.8-10 
 In the present study, the scratching behavior caused by 
an allergic cutaneous reaction in mice was investigated 
according to the method reported by Kuraishi et al.5 and 
attempts were made to pharmacologically characterize 
the scratching behavior.
METHODS 
Animals 
Female BALB/c mice, 8-9 weeks old, purchased from 
Japan SLC (Hamamatsu, Japan) were used throughout.
Antigen 
2,4-Dinitrofluorobenzene, purchased from Nacalai 
Tesque (Kyoto, Japan), was used as an antigen; it was 
dissolved in a mixture of acetone and olive oil (3:1).
Monoclonal IgE 
Mouse monoclonal IgE against DNP residue was 
prepared by culturing a cell line, ECl, as previously 
reported.8 The culture supernatant of ECl was stored at
-80℃ and was used as a source of IgE. The maximum
dilution of the IgE preparation to give a positive 
cutaneous anaphylaxis in Wistar rats challenged with 
DNP-conjugated bovine serum albumin was 1:1024. 
The IgE content of the preparation, estimated by enzyme-
linked immunosorbent assay, was 1415ng/mL.
Drugs 
3-[4-(8-Fluoro-5,11-dihydro [1] benzoxepino [4,3-b] 
pyridin-11-ylidene) piperidino] propionic acid (HSR-
609), a novel amphoteric antiallergic agent with a potent 
and long-lasting histamine H,-receptor antagonistic 
property,11 and cetirizine dihydrochloride12,13 were 
synthesized by Hokuriku Seiyaku Co. Ltd (Fukui, Japan). 
Terfenadine14 was purchased from Sigma Chemical Co. 
(St Louis, MO, USA). These agents were suspended in 5% 
arabic gum solution. Naloxone hydrochloride (Sigma
Chemical Co.), cyproheptadine hydrochloride (Nacalai 
Tesque), dibucaine hydrochloride (Nacalai Tesque) and 
compound 48/80 (Sigma Chemical Co.) were dissolved 
in physiological saline. Prednisolone acetate (Shionogi 
Pharmaceutical Co. Ltd, Osaka, Japan) was also 
suspended in physiological saline. HSR-609, cetirizine, 
terfenadin  and cyproheptadine were administered orally 
to mice 1h prior to the elicitation of any reaction. 
Naloxone was given intravenously 1h before the 
re ction. Prednisolone was injected intraperitoneally 2h 
before the reaction. Dibucaine was given to mice 
subcutaneously at the time of stimulation.
DNFB-induced scratching behavior 
2,4-Dinitrofluorobenzene treatment in sensitized mice 
was performed as reported previously8-10 with a slight 
modification. Briefly, mice received an intravenous 
injection of 1.0mL monoclonal IgE preparation. Twenty-
four hours after passive sensitization, DNFB acetone-
olive oil solution was applied to both sides of the ears. 
Although we have observed mouse biphasic cutaneous
re ctions after applying 25μL of a 0.15% DNFB
solution, a high incidence of scratching was observed 
even in non-sensitized mice under such experimental 
conditions. We therefore painted 5uL of a 0.75% DNFB 
solution on both sides of the ear to reduce non-specific 
scratching when examining scratching behavior. 
Immediately after antigen application, mice were put into
acr lic cages (30×30×12cm) and their behavior was
observed. Instances of scratching of the ear lobes by the 
hind paws were counted. The mice showed several 
scratchings for approximately 1s and a series of these 
behaviors was counted as one incident of scratching 
according to the method described by Kuraishi et al.5
48/80-induced scratching behavior
48/80 solution in a volume of 100μL wos injected
subcutaneously into the rostral part of the back of mice.5 
Immediately after injection of 48/80, mice were put into 
acrylic cages and scratching behaviors were counted as 
mentioned above.
DNFB-induced edematous reaction 
An IgE-dependent cutaneous reaction was performed in 
the mouse ear as reported previously.8-10 The ear edema 
caused by the application of DNFB was evaluated by
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measuring the ear thickness by a micrometer (Peacock 
Upright Dial Gauge, Ozaki, Tokyo, Japan) before and 1 
h after antigen challenge. 
Statistics
Data are expressed as the mean±SEM. Statistical
comparisons were made by parametric Duncan's 
multiple range test, using the computer software YUKMS 
(version 5.0; Kanagawa, Japan) and P<0.05 was taken 
to indicate significance.
RESULTS 
DNFB-induced scratching behavior in 
sensitized mice 
Figure 1a shows the results of a time course study of 
scratching behavior for 120min after DNFB or vehicle 
application to the ears of sensitized or intact mice. 
Scratching behavior was caused by DNFB application 
itself in intact mice in comparison with vehicle-treated 
controls. The number of scratchings, however, 
significantly increased from 60 to 120min after 
application of DNFB in sensitized mice compared with 
DNFB-treated intact mice. The incidence of scratching 
behavior declined thereafter (data not shown). Based on 
these results, scratching behavior was observed for 120 
min in the following experiments.
 As shown in Fig. 1b, prednisolone at doses of 1 and 3 
mg/kg significantly inhibited scratching for 120min in a 
dose-related manner. 
 Results of administration of HSR-609, cetirizine and 
terfenadine are shown in Fig, 1c-e. These three 
antihistamines only showed a tendency to inhibit 
scratching. The degree of inhibition of scratching for 120 
min by HSR-609 (1mg/kg), cetirizine (0.1mg/kg) and 
terfenadine (100mg/kg) was 41.2, 31.0 and 29.9%, 
respectively. In contrast to the antihistamines, cypro-
heptadine, an antagonist against histamine H1- and 
serotonin receptors, at a doses of 10mg/kg significantly 
inhibited the 120min scratching counts (Fig. 1f).
 Results of administration of the local anesthetic 
dibucaine are shown in Fig. 1g. Dibucaine, at a dose of
300μg/site, significantly inhibited the scratching counts
for 120min, but did not inhibit scratching at a dose of 30
μg/site. Naloxone, an opiate receptor antagonist, at a
dose of 3mg/kg also significantly inhibited scratching 
counts for 120min (Fig. 1h).
48/80-induced scratching in mice 
When BALB/c mice received an injection of 48/80 at
doses of 10 and 100μg into the rostral part of the back,
they exhibited scratching of or around the injected site by 
the hind paws. The first scratching behavior appeared 
within 10min after injection and lasted intermittently for
30min. 48/80 at 100μg was effective in causing
scratching, but was less effective at 10μg. A dose of 1
μg 48/80 failed to induce scratching (Fig. 2a). The
incidence of scratching caused by 100μg 48/80 peaked
between 10 and 15min. As we had confirmed in 
preliminary experiments that the incidence of 48/80-
induced scratching was low later than 45min after its 
injection (data not shown), mouse behavior was only 
observed for 45min after injection of 48/80 in the pre-
sent experiments. In the following experiments, scratching
behaviorwas caused by injecting 100μg 48/80.
 Results of administration of prednisolone are shown in 
Fig. 2b. Prednisolone failed to affect 48/80-induced 
scratching behavior in mice. 
 As shown in Fig. 2c-e, HSR-609, cetirizine and 
terfenadine did not affect 48/80-induced scratching in 
mice. In contrast to these antihistamines, cyproheptadine, 
at a dose of 10mg/kg, significantly inhibited 48/80-
induced scratching (Fig. 2f).
Results of dibucaine administration are shown in Fig.
2g. Dibucaine, at doses of 30 and 300μg/site,
significantly inhibited scratching for 45min in a dose-
related manner. As shown in Fig. 2h, naloxone at 10 
mg/kg also significantly inhibited scratching behavior.
DNFB-induced edematous reaction in 
sensitized mice 
Application of DNFB in the ear of sensitized mice caused 
a transient edematous reaction. The ear edema peaked 
1h after antigen challenge and declined thereafter (data 
not shown). Drug effects on ear edema, estimated at 1h, 
are shown in Fig. 3. 
 Prednisolone at doses of 1 and 3mg/kg potently 
inhibited ear edema. Three antihistamines, HSR-609 (at 
0.1 and 1mg/kg), cetirizine (at 0.1 and 1mg/kg) and 
terfenadine (at 10 and 100mg/kg), significantly inhibited 
ear edema. Cyproheptadine at a dose of 30mg/kg also 
signific ntly inhibited the development of ear edema. 
However, dibucaine and naloxone did not affect the 
development of ear edema.
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DISCUSSION 
In the present study we demonstrated that scratching by 
the hind paws could be induced by epicutaneous 
challenge with DNFB in mice passively sensitized with
monoclonal IgE and we pharmacologically characterized 
this scratching behavior. Previously we have indicated 
that the IgE-dependent allergic cutaneous reaction is a 
suitable animal model for investigating the mechanism of 
allergic dermatitis, particularly the cutaneous late-phase
Fig. 1 2,4-Dinitrofluorobenzene 
(DNFB)-induced scratching in sensi-
tized mice and the effects of various 
drugs on scratching. Mice were 
sensitized with anti-dinitrophenol IgE 
and were challenged with DNFB. 
Scratching behavior was counted for 
120min after DNFB application. (a)
SCRATCHING BEHAVIOR IN MICE 121
reaction.8-10 The present results indicate that this model 
may also be suitable for investigating pruritus caused by 
allergic dermatitis. 
In 1995, Kuraishi et al.5 reported that 48/80 induces 
scratching by the hind paws in ddY mice and that the
scratching behavior is due to itch but not to pain. In 
human subjects, an intradermal or subcutaneous 
injection of 48/80 is also known to cause an itch 
sensation with a short duration.15-17 Therefore, 
we examined scratching behavior due to an allergic
Fig. 2 48/80-induced scratching in 
mice and effects of various drugs on 
the scratching. Scratching behavior 
was counted for 45min after a 
subcutaneous injection of 48/80. (a)
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reaction in comparison with 48/80-induced scratching. 
 Although the first scratching behavior caused by 48/80 
was observed within 10min after its injection, as reported 
by Kuraishi et al.,5 the scratching behavior after DNFB
application took some time to develop, which may be 
related to the period required for DNFB to penetrate 
through the skin. 2,4-Dinitrofluorobenzene application 
itself caused scratching behavior in non-sensitized mice.
Fig. 3 Effects of various drugs on the 
2,4-dinitrofluorobenzene (DNFB)-
induced edematous reaction in 
sensitized mice. Mice were sensitized 
with anti-dinitrophenol IgE and were 
challenged with DNFB. The ear 
edema caused by the application of 
DNFB was evaluated by measuring 
ear thickness 1h after antigen 
challenge. Each column and bar
represent the mean±SEM of four to
eight mice. **P<0.01.
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Vehicle application also caused scratching behavior in 
mice, although the incidence was lowerthan that induced 
by application of DNFB. In sensitized mice, however, the 
number of scratchings apparently increased from 60min 
after DNFB application in comparison with non-
sensitized control mice, indicating that the IgE-mediated 
allergic cutaneous reaction could be accompanied by 
scratching behavior in mice. 2,4-Dinitrofluorobenzene 
application to sensitized mice causes a biphasic ear 
edema with peak responses at 1 and 24h after 
challenge.6-9 The early phase edema was suppressed by 
mast cell stabilizers and antihistamines, and was not 
evoked in mast cell-deficient WBB6F1-W/Wv mice. The 
presence of degranulated mast cells has been confirmed 
in the early phase edema. In contrast, the late-phase
edema was characterized by infiltration of neutrophils 
and macrophages. Therefore, DNFB-induced scratching 
behavior observed in the present study may be correlated 
to the mast cell-dependent immediate-phase edema, 
although the scratching behavior seemed to develop 
slightly slower than did the edema. Although the present 
data clearly indicate that a scratching behavior can be 
caused in mice in association with an IgE-mediated 
allergic cutaneous reaction, we could not distinguish the 
IgE-mediated scratching from non-specific scratching 
under present experimental conditions. Therefore, we 
need to revise the experimental conditions to reduce non-
specific scratching. Furthermore, as DNFB application 
itself caused scratching behavior, it may become another 
model for investigating scratching.
 Histamine has been considered to be the most 
important substance for causing itch in humans18 and, in 
most cases, histamine H1-receptor antagonists are 
effective for the treatment of pruritus.19 In the present 
study, however, three histamine H1-receptor antagonists 
(HSR-609,11 cetirizine12,13 and terfenadine14) did not 
significantly affect scratching in mice caused by either 
DNFB application or 48/80 injection, although 
cyproheptadine clearly inhibited scratching. These results 
suggest that histamine antagonism may not be effective 
in inhibiting scratching in mice and that serotonin may 
participate in the induction of scratching. In contrast, the 
edematous reaction caused by the application of DNFB 
in sensitized mice was potently inhibited by all these 
agents, indicating that histamine and serotonin play an 
important role in inducing edema.9 In sensitized mice, 
mast cells are activated following challenge with DNFB to 
release various mediators, including histamine and 
serotonin,20 and the vasoactive amines cause an
edematous reaction. Therefore, histamine plays an 
important role in DNFB-induced cutaneous edema, 
whereas it does not seem to have a central role in 
causing scratching. However, serotonin may play 
important roles in the development of both edema and 
scratching. We need to undertake further experiments 
using selective serotonin antagonists to elucidate the role 
of serotonin in DNFB-induced scratching. Furthermore, 
scratching itself may cause mediator release from mast 
cells as a physical stimulus and may potentiate the 
edematous reaction. In preliminary experiments,
however, application of 25μL of a 0.15% DNFB solution
caused a high incidence of scratching without causing 
any edematous response in non-sensitized mice, 
suggesting that the scratching may not affect the 
edematous reaction under present experimental con-
ditions. We also need to carefully evaluate the effect of 
scratching on the edematous response in the mouse ear. 
 Prednisolone, a potent anti-inflammatory drug, 
significantly inhibited DNFB-induced scratching and 
d ma, whereas it did not affect 48/80-induced 
scratching. Prednisolone inhibits the activation of various 
inflammatory cells and the subsequent production and
release of inflammatory mediators.21,22 The application of 
DNFB to sensitized mice is considered to cause the 
activation of various cells in the skin, including sensitized 
mast cells, and results in the induction of edema and 
scratching. Prednisolone may inhibit the induction of 
edema and scratching by suppressing the activation of 
the cells involved in their development.10 In contrast, 
48/80 may cause scratching more directly than in the 
case of DNFB. 
 Dibucaine inhibited the scratching caused by both 
DNFB and 48/80, probably by blocking the itch 
sensation pathway, although this pathway is not yet 
established. Further experiments should be undertaken to 
demonstrate the existence of afferent nerve systems for 
sensitive itching. In contrast, opioids exhibit an analgesic 
action but enhance the itch sensation.23,24 There are some
r ports that indicate the effectiveness of opiate 
a tagonists for the treatment of itching in hepatic 
diseases.25,26 Therefore, endogenous opioids may 
participate in the generation of the itch sensation and 
naloxone may act as an antagonist against endogenous 
o ioids. Nevertheless, the mechanism of action of 
naloxone is still obscure; naloxone apparently inhibited 
both DNFB- and 48/80-induced scratching, suggesting 
that scratching behavior in mice induced by both DNFB 
and 48/80 share a common induction pathway.
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 The present results indicate that scratching behavior 
could be induced in mice in association with an IgE-
mediated allergic cutaneous reaction and that the 
reaction is pharmacologically similar, but not identical, to 
that caused by 48/80. Although histamine is considered 
to participate in the formation of ear edema, it does not 
seem to play an important role in the generation of 
scratching. This animal model may serve as a model for 
pharmacological studies on allergic itch and as a model 
for research on antipruritus agents.
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